Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ERErasca, Inc. logo

Erasca, Inc. (ERAS)

NASDAQ Global Select · Currency in USD
$14.39 ▲ +0.35 (+2.49%)
At close: Oct 23, 4:00 PM ET. Market closed.
$14.25 ▼ -0.14 (-0.97%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$14.04
Open
$13.97
Day's Range
$13.44 – $14.45
52 Week Range
$2.11 – $24.28
Volume
3,499,872
Avg. Volume
4,808,614
Market Cap
$5.03B
Beta (5Y Monthly)
0.62
PE Ratio (TTM)
--
EPS (TTM)
-$0.92
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$22.50

Profile: Erasca, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
103
CEO
Jonathan E. Lim
Website
erasca.com

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.13
DateEst.Actual
Aug 12, 2026-$0.11-$0.14Miss
May 11, 2026-$0.11-$0.60Miss
Mar 12, 2026-$0.11-$0.10Beat
Nov 12, 2025-$0.11-$0.11Beat
Aug 12, 2025-$0.12-$0.12Beat
May 13, 2025-$0.12-$0.11Beat

Analyst view

Consensus price target
$22.50 ▲ +56.4%
Range $16.00 – $30.00
Rating: Buy
Buy 82% · Hold 18% · Sell -0%

Get free alerts on ERAS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.